• Explore /
  • Poster
  • / Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).

Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).

Abstract Poster

Authors

null

Nick Van Dijk

The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

Nick Van Dijk , Alberto Gil Jimenez , Karina Silina , Kees Hendricksen , Laura Smit , Jeantine De Feijter , Maurits L van Montfoort , Annegien Broeks , Yoni Lubeck , Karolina Sikorska , Thierry N. Boellaard , Pia Kvistborg , Daniel J Vis , Erik Hooijberg , Ton Schumacher , Maries van den Broek , Lodewyk FA Wessels , Christian U. Blank , Bas W.G. van Rhijn , Michiel Simon Van Der Heijden

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT03387761

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5020)

DOI

10.1200/JCO.2020.38.15_suppl.5020

Abstract #

5020

Poster Bd #

89

Abstract Disclosures

Similar Posters

First Author: Charlee Nardin

Poster

2018 ASCO Annual Meeting

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

First Author: Nathaniel R. Evans

First Author: Vadim S Koshkin

First Author: Evangelia Vlachou